News
BioSpace Denatured podcast – The next treatment-resistant depression paradigm
August 6, 2026

BioSpace Denatured podcast – The next treatment-resistant depression paradigm

CMO Hans Eriksson highlights FundaMental Pharma's innovative approach to restoring neuroplasticity in treatment-resistant depression and its potential to address significant unmet patient need.
Technology Networks – Investigational Drug Could Provide At-Home Treatment-Resistant Depression Care
July 14, 2026

Technology Networks – Investigational Drug Could Provide At-Home Treatment-Resistant Depression Care

CMO Hans Eriksson discusses the challenges of developing new treatments for treatment-resistant depression and the potential of dual-acting NMDA receptor modulation to address current gaps…
FundaMental Pharma appoints depression drug developer Dr. Hans Eriksson as Chief Medical Officer to advance its lead treatment-resistant depression candidate
June 2, 2026

FundaMental Pharma appoints depression drug developer Dr. Hans Eriksson as Chief Medical Officer to advance its lead treatment-resistant depression candidate

Exceptional track record across multiple clinical development programs for depression, three of which have resulted in regulatory approvals Appointment strengthens confidence in clinical readiness and…
pharmaphorum – Anglonordic Life Science 2026: A Focus On Execution
May 6, 2026

pharmaphorum – Anglonordic Life Science 2026: A Focus On Execution

Reflections on key discussions from Anglonordic Life Science 2026, including biotech investment trends and the importance of execution in today's market.
Base to Base Biotech Podcast – 57: Keeping drugs cool, and treatment-resistant depression
May 1, 2026

Base to Base Biotech Podcast – 57: Keeping drugs cool, and treatment-resistant depression

A conversation covering treatment-resistant depression, current challenges in drug development, and the science behind FundaMental Pharma's research.
BiotechTV – From Germany: FundaMental Pharma aims to develop a dual-acting NMDA receptor modulator for treatment-resistant depression to improve on the risk profile seen today with esketamine
April 30, 2026

BiotechTV – From Germany: FundaMental Pharma aims to develop a dual-acting NMDA receptor modulator for treatment-resistant depression to improve on the risk profile seen today with esketamine

An interview exploring the unmet need in treatment-resistant depression and FundaMental Pharma's approach to developing next-generation therapies for patients.
BioWorld – With improved technologies, biomarkers, failed drugs may come into their own
March 24, 2026

BioWorld – With improved technologies, biomarkers, failed drugs may come into their own

Industry experts at BioEurope Spring 2026 discuss the future of neuropsychiatric and neurodegenerative diseases drug development and how new technologies and biomarkers could help improve…
Labiotech – Brain Awareness Week: could ongoing R&D spur neuroscience breakthroughs?
March 18, 2026

Labiotech – Brain Awareness Week: could ongoing R&D spur neuroscience breakthroughs?

As part of Brain Awareness Week, FundaMental Pharma’s CEO Dirk Beher discussed the potential of clinically validated pathways to address treatment-resistant depression.
Drug Target Review – Why NMDA receptor modulation remains central to next-generation depression therapies
March 17, 2026

Drug Target Review – Why NMDA receptor modulation remains central to next-generation depression therapies

A discussion on the potential of NMDA receptor modulation in depression research and emerging strategies for targeting this key pathway.
European Biopharmaceutical Review – Modulating neuroplasticity to address unmet medical needs in CNS disorders
March 11, 2026

European Biopharmaceutical Review – Modulating neuroplasticity to address unmet medical needs in CNS disorders

Exploring the role of neuroplasticity in brain disorders and its potential to unlock new therapeutic approaches for patients with CNS diseases.
FundaMental Pharma appoints depression drug developer Dr. Hans Eriksson as Chief Medical Officer to advance its lead treatment-resistant depression candidate
June 2, 2026

FundaMental Pharma appoints depression drug developer Dr. Hans Eriksson as Chief Medical Officer to advance its lead treatment-resistant depression candidate

Exceptional track record across multiple clinical development programs for depression, three of which have resulted in regulatory approvals Appointment strengthens confidence in clinical readiness and…
FundaMental Pharma to showcase groundbreaking approach to treatment-resistant depression at Bio-Neuroscience Conference
February 17, 2026

FundaMental Pharma to showcase groundbreaking approach to treatment-resistant depression at Bio-Neuroscience Conference

Presentation will highlight lead clinical candidate FMP374, a novel dual-acting NMDAR modulator advancing toward IND-enabling studies for TRD Heidelberg, Germany – 17 February 2026 – FundaMental…
FundaMental Pharma appoints Dr. Dirk Beher as Chief Executive Officer
April 11, 2024

FundaMental Pharma appoints Dr. Dirk Beher as Chief Executive Officer

Highly experienced biotech executive, with over a quarter of a century of CNS drug discovery experience Beher takes over the role of Chief Executive Officer…
FundaMental Pharma Appoints Industry Veteran Dr. Lorenz Mayr as Non-Executive Director
March 20, 2024

FundaMental Pharma Appoints Industry Veteran Dr. Lorenz Mayr as Non-Executive Director

Appointment underscores FundaMental’s ambition to develop medicines for neurodegenerative diseases based on a breakthrough molecular mechanism Heidelberg, GERMANY, 20 March 2024 - FundaMental Pharma GmbH,…
FundaMental Pharma launches with EUR 10 million in Seed financing led by BGV and Thuja Capital to advance a First-in-Class neuroprotectant
November 17, 2022

FundaMental Pharma launches with EUR 10 million in Seed financing led by BGV and Thuja Capital to advance a First-in-Class neuroprotectant

Heidelberg, Germany – 17 November 2022 – FundaMental Pharma GmbH (“FundaMental”), a preclinical neuroscience company spun out of Heidelberg University, today announces that it has launched…
BioSpace Denatured podcast – The next treatment-resistant depression paradigm
August 6, 2026

BioSpace Denatured podcast – The next treatment-resistant depression paradigm

CMO Hans Eriksson highlights FundaMental Pharma's innovative approach to restoring neuroplasticity in treatment-resistant depression and its potential to address significant unmet patient need.
Technology Networks – Investigational Drug Could Provide At-Home Treatment-Resistant Depression Care
July 14, 2026

Technology Networks – Investigational Drug Could Provide At-Home Treatment-Resistant Depression Care

CMO Hans Eriksson discusses the challenges of developing new treatments for treatment-resistant depression and the potential of dual-acting NMDA receptor modulation to address current gaps…
pharmaphorum – Anglonordic Life Science 2026: A Focus On Execution
May 6, 2026

pharmaphorum – Anglonordic Life Science 2026: A Focus On Execution

Reflections on key discussions from Anglonordic Life Science 2026, including biotech investment trends and the importance of execution in today's market.
Base to Base Biotech Podcast – 57: Keeping drugs cool, and treatment-resistant depression
May 1, 2026

Base to Base Biotech Podcast – 57: Keeping drugs cool, and treatment-resistant depression

A conversation covering treatment-resistant depression, current challenges in drug development, and the science behind FundaMental Pharma's research.
BiotechTV – From Germany: FundaMental Pharma aims to develop a dual-acting NMDA receptor modulator for treatment-resistant depression to improve on the risk profile seen today with esketamine
April 30, 2026

BiotechTV – From Germany: FundaMental Pharma aims to develop a dual-acting NMDA receptor modulator for treatment-resistant depression to improve on the risk profile seen today with esketamine

An interview exploring the unmet need in treatment-resistant depression and FundaMental Pharma's approach to developing next-generation therapies for patients.
BioWorld – With improved technologies, biomarkers, failed drugs may come into their own
March 24, 2026

BioWorld – With improved technologies, biomarkers, failed drugs may come into their own

Industry experts at BioEurope Spring 2026 discuss the future of neuropsychiatric and neurodegenerative diseases drug development and how new technologies and biomarkers could help improve…
Labiotech – Brain Awareness Week: could ongoing R&D spur neuroscience breakthroughs?
March 18, 2026

Labiotech – Brain Awareness Week: could ongoing R&D spur neuroscience breakthroughs?

As part of Brain Awareness Week, FundaMental Pharma’s CEO Dirk Beher discussed the potential of clinically validated pathways to address treatment-resistant depression.
Drug Target Review – Why NMDA receptor modulation remains central to next-generation depression therapies
March 17, 2026

Drug Target Review – Why NMDA receptor modulation remains central to next-generation depression therapies

A discussion on the potential of NMDA receptor modulation in depression research and emerging strategies for targeting this key pathway.
European Biopharmaceutical Review – Modulating neuroplasticity to address unmet medical needs in CNS disorders
March 11, 2026

European Biopharmaceutical Review – Modulating neuroplasticity to address unmet medical needs in CNS disorders

Exploring the role of neuroplasticity in brain disorders and its potential to unlock new therapeutic approaches for patients with CNS diseases.
BioXconomy – FundaMental CEO tells all about biotech fundraising in neuroscience
February 2, 2026

BioXconomy – FundaMental CEO tells all about biotech fundraising in neuroscience

CEO Dirk Beher discusses FundaMental Pharma's fundraising journey, the company's financing strategy, and lessons learned for emerging neuroscience companies.
A New Villain in Neuronal Death – A newly discovered partnership for glutamate triggers brain toxicity
October 9, 2020

A New Villain in Neuronal Death – A newly discovered partnership for glutamate triggers brain toxicity

Jones S A New Villain in Neuronal Death – A newly discovered partnership for glutamate triggers brain toxicity Science 370, eaay3302 , doi: 10.1126/science.abe2791. Abstract…
Coupling of NMDA receptors and TRPM4 guides discovery of unconventional neuroprotectants
October 9, 2020

Coupling of NMDA receptors and TRPM4 guides discovery of unconventional neuroprotectants

Yan J, Bengtson P, Buchthal B, Hagenston A, Bading H. Coupling of NMDA receptors and TRPM4 guides discovery of unconventional neuroprotectants. Science 370, eaay3302 ,…